Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic LeukemiaSusanne Badura(Goethe University Frankfurt), Oliver G. Ottmann(Goethe University Frankfurt)PLoS ONENovember 14, 201310.1371/journal.pone.0080070Cited by 70SaveCiteExport RISWatch citationsRelated PapersKinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)|Blood|2007|249